Pure Global
NCT06128460

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer (IB3, IIA2) Patients
Obstetrics & Gynecology Hospital of Fudan University·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cervical Cancer
Drug/Device/Intervention
Zimberelimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Obstetrics & Gynecology Hospital of Fudan University
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2023
End date
Dec 01, 2029
Enrollment
24 participants
Primary outcome

changes in tumor-related biomarkers

Summary

Locally advanced cervical cancer (stage IB3, IIA2) patients with postoperative risk factors
 need better treatment. We initiated a clinical study to explore the effectiveness of adjuvant
 chemoradiotherapy followed by Zimberelimab for these patients.

ICD-10 classifications
Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06128460
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06128460 through Pure Global AI's free database. This Phase 2 trial is sponsored by Obstetrics & Gynecology Hospital of Fudan University and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.